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Tumor molecular profiling is often performed in order to direct cancer treatment options. However, 
because many of the genes analyzed on tumor molecular profiling overlap with genes known to be 
associated in the germline with hereditary cancer predisposition syndromes, tumor molecular profiling 
can unknowingly uncover germline predisposition to cancer development. In this study, we determined 
the number of patients with pathogenic variants (PVs) identified in BRCA1 and BRCA2 (BRCA1/2) via 
tumor molecular profiling at The University of Texas MD Anderson Cancer Center, then performed a 
retrospective chart review to determine the proportion of such patients that received germline testing and 
had germline PVs identified. We found that 3.78% (13/2,990; 95% CI 3.09-4.46%) of tumor-only testing 
reports identified PVs in BRCA1/2, 38.94% (44/113; 95% CI 29.95-47.93%) of patients with pathogenic 
variants in BRCA1/2 had germline testing, and 63.64% (28/44; 95% CI 49.42-77.85%) of patients with 
germline testing had germline PVs in BRCA1/2. Patients with cancer diagnoses related to BRCA1/2 were 
more likely to have had germline testing (72.73% of patients with testing had HBOC-related tumors vs. 
36.23% of those without testing, p <0.001). Efforts to improve testing yield should focus on increasing 
awareness and availability of germline testing for advanced cancer patients with tumor-identified 
BRCA1/2 mutations, particularly in non-BRCA1/2 associated cancer types.  
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Tumors are often subject to genetic testing in order to obtain a somatic mutation profile that can 
influence treatment. There are two broad categories of tumor molecular profiling methods. The first 
method is tumor-normal paired testing, in which tumor tissue and unaffected tissue are analyzed 
concurrently and compared to determine if variants identified originate in the tumor (referred to as 
somatic for the remainder of the paper) or are constitutionally present (hereafter referred to as 
“germline”). The other is tumor-only testing, in which it cannot be determined conclusively whether a 
variant is somatic or germline. Many of the genes analyzed within tumors to direct treatment also have 
significant hereditary cancer implications when pathogenic variants are present in the germline. For 
example, BRCA1 and BRCA2 are commonly analyzed in tumor samples, because targeted therapies such 
as PARP inhibitors may be considered for tumors with variants identified in BRCA1/2. However, 
pathogenic variants in BRCA1 and BRCA2 also cause Hereditary Breast and Ovarian Cancer syndrome 
(HBOC) when they are present in the germline. HBOC is a genetic condition characterized by an 
increased lifetime risk of breast, ovarian, pancreatic, and prostate cancer. Given the overlap between 
genes that are analyzed in tumor profiling and genes that are associated with hereditary cancer 
predisposition syndromes (HCPS), tumor profiling can unknowingly report tumor-detected mutations 
that in fact represent an underlying HCPS. 
 
Studies of tumor-normal paired testing have provided insight into how often tumor-detected 
mutations are present in the germline. In a group of unselected cancer patients who underwent tumor-
normal paired testing, approximately 3% of patients had germline pathogenic variants (PVs) associated 
with HCPS3. In a study performed at MD Anderson Cancer Center, 4.3% of patients were found to have 
germline PVs in 19 genes associated with high penetrance HCPS, following concurrent analysis of tumor 
and normal tissue in a cohort of advanced cancer patients7. A study performed with a similar cohort at 
Memorial Sloan Kettering revealed that 17.5% of patients with advanced cancer had clinically actionable 
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germline PVs in 76 genes of low, moderate, or high cancer risk that were identified using tumor-normal 
paired testing5.  
 
Studies have also determined how often germline PVs in specific genes are identified following 
tumor profiling. It has been established through tumor-normal paired testing that mutations in the genes 
TP53, APC, and PTEN are commonly somatically mutated in an unselected cohort of advanced cancer 
patients, as 86.6% of variants with clinical significance identified across 1,000 tumors were identified in 
one of these three genes, and only 2.8% were germline7. This same study also established that 77.78% of 
pathogenic variants in BRCA1/2 detected on tumor molecular profiling were germline in origin7. Another 
study published in the same year supported this evidence by demonstrating that 64.5% of patients with 
pathogenic variants identified in BRCA1/2 in breast cancer tissue were germline9. This led to a change in 
NCCN guidelines recommending that PVs in BRCA1/2 identified via tumor-only testing receive follow-
up germline testing12.  
 
Tumor molecular profiling may be the first indication that a patient has HCPS, as many current 
guidelines that are based on evaluation of personal history, family history, and pathology are missing a 
significant number of patients with HCPS. Several studies have indicated that over 50% of patients 
identified by tumor-normal paired testing with germline PVs in genes associated with HCPS would be 
missed by current guidelines based on evaluation of personal and family history5,7. Additionally, a 
population based germline sequencing study of BRCA1 and BRCA2 that was performed by Geisinger 
revealed that approximately 50% of all patients with identified pathogenic or likely pathogenic variants 
did not meet current clinical guidelines based on personal and family history6.   
 
While tumor-normal paired testing readily distinguishes somatic from germline PVs, tumor-only 
testing is more commonly used in the clinical setting in order to limit cost and turnaround time8. Because 
the germline is contained in the tumor DNA, it is important to understand what type of information 
patients may receive from tumor-only testing to ensure that they are being adequately informed and 
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consented4,8. There are few studies to date analyzing the identification of HCPS following tumor-only 
testing. In one such study, Catenacci et al. evaluated how frequently patients that underwent tumor 
profiling via FoundationOne tumor profiling panel were found to have germline PVs2. Seven of 111 
patients that were deemed “high risk” after their tumor profiling subsequently received follow-up 
germline testing. Three had germline PVs, all of which were identified in BRCA2. Therefore, 2.7% of the 
initial cohort that underwent tumor-only testing was found to have a pathogenic germline variant. 
Because this study was limited in its size and scope, more research on the subject is warranted.  
 
Because studies using tumor-normal paired testing have shown that patients with germline PVs are 
being missed by clinical guidelines for germline testing, and because tumor-only testing is a more 
commonly utilized tumor analysis platform, it is paramount to patient care that the hereditary cancer 
implications of tumor-only testing are well understood. We performed a retrospective chart review to 
determine how frequently pathogenic variants are identified in BRCA1 and BRCA2 via tumor-only 
testing, what proportion of those patients receive germline testing, and how often the germline testing 




We performed a retrospective chart review for a cohort of 2,991 patients seen at The University of 
Texas MD Anderson Cancer Center in Houston, TX that have received FoundationOne testing. Patients 
with reports available that were ordered from September 7, 2012, to August 17, 2018 were included in 
the study. The first NCCN recommendation for germline testing for BRCA1/2 in patients with “BRCA1/2 
mutation detected by tumor profiling in the absence of germline mutation analysis” was published on 




Figure 1. Variant calling algorithm
 
 
Variant interpretation was established according to an algorithm established by the group 
(Figure1). The first source used to interpret variants was ClinVar, a database for germline variant 
interpretation, publicly available through the NIH (https://www.ncbi.nlm.nih.gov/clinvar/). 
Interpretations were recorded when available.  Any variants that were reported by ClinVar as 
“Conflicting Interpretation” between pathogenic/likely pathogenic and VUS or benign were recorded as 
such. If there was no interpretation data available through ClinVar, a general algorithm was applied to 
classify the remaining variants. Truncating mutations (e.g. frameshifts, large deletions, and nonsense 
mutations) not located close to the 3’ end of the protein were determined to be “inferred pathogenic.” 
Missense mutations, intronic variants, or any other variants that were unable to be labeled “inferred 
pathogenic” mutations were labeled “inferred VUS.” 
 
Patients with variants identified via tumor-only testing that were determined to be pathogenic were 
subjected to a chart review. Information was collected about demographic information and follow-up 
germline testing. An HBOC-related primary tumor was considered one identified in the breast, 
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ovaries/fallopian tubes, peritoneum, pancreas, or prostate. A significant family history was defined as a 
first-degree relative or two second degree relatives with any HBOC-related cancer, any female relative 
within three degrees of relation with ovarian cancer, or any male relative within three degrees of relation 
with breast cancer. Statistics were performed using Stata11. Statistical significance was determined using 
chi squared analysis or t-tests. Significance was assumed at p < 0.05, and statistics were calculated at a 




This study included 2,990 patients with tumor-only testing. Of these, a subgroup was identified in 
which 457 patients (457/2,990; 15.28%; 95% CI 13.99-16.57%) were found to have any BRCA1/2 
variants noted on the report. In this subgroup, 341 (341/457; 74.62%; 95% CI 70.63-78.61%) had 
variants classified as benign, likely benign, VUS, or inferred VUS. Three patients had variants 
interpreted in ClinVar as conflicting between VUS and pathogenic (3/457; 0.66%; 95% CI 0.136-
1.91%). A total of 113 patients had tumor molecular profiling reports with pathogenic, likely pathogenic, 
or inferred pathogenic variants in BRCA1/2 (113/2,990; 3.78%; 95% CI 3.09-4.46%). This group will be 
referred for the remainder of the paper as patients with clinically significant variants on tumor-only 
testing, as per proposed standards and guidelines14. The group of individuals with clinically significant 
variants on tumor molecular profiling were compared to the larger cohort of 2,990 patients to identify 
any areas in which the groups may be statistically significantly different (Table 1).  Primary tumor site 
was found to be significantly different (p < 0.001). Of note, 80.53% of the cohort with clinically 
significant variants on tumor-only testing had testing prior to the NCCN guideline change in December 
2016. 
 
In the group of patients with clinically significant variants identified, 44 (44/113; 38.94%; 95% CI 
29.95-47.93%) had record of germline testing for BRCA1/2, and 28 were positive (28/44; 63.64%; 95% 
CI 49.42-77.85%). Those that have received germline testing can be further broken down into those that 
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had germline testing before tumor-only testing, and those that had germline testing after tumor-only 
testing. Eleven (11/44; 25%; 95% CI 12.21-37.79%) patients received germline testing after their tumor 
molecular profiling, and 33 (33/44; 75%; 95% CI 62.21-87.79%) received germline testing before 
(Figure 2). 
 




Table 1: Characteristics of patients with pathogenic variants in BRCA1 and BRCA2 identified on 
tumor-only testing 
Parameters Patients with pathogenic 
variants identified on 
tumor-only testing              
(n = 113) 




Median age at cancer diagnosis (range) 53 (17-79) 55 (2-86) 0.6535 
Sex, n (%)   0.051 
Female 74 (65.49) 1,624 (54.33)  
Male  39 (34.51) 1,362 (45.57)  
Unknown 0 (0.00) 3 (0.10)  
Race/Ethnicity, n (%)   0.926 
White 85 (75.22) 2,284 (76.39)  
Black/African American 10 (7.96) 213 (7.12)  
Hispanic 3 (2.65) 132 (4.41)  
Asian 6 (5.31) 134 (4.48)  
Hawaiian/Pacific Islander 1 (0.88) 16 (0.54)  
Native American 0 (0.00) 3 (0.10)  
Other 4 (3.54) 77 (2.58)  
Unknown  4 (3.54) 131 (4.38)  
Primary tumor site, n (%)   < 0.001 
Breast 24 (21.24) 294 (9.83)  
Bile duct|Cholangiocarcinoma 15 (13.27) 361 (12.07)  
Ovarian 15 (13.27) 114 (3.81)  
Colorectal 7 (6.19) 117 (5.92)  
Pancreatic 7 (6.19) 112 (3.75)  
Prostate 5 (4.42) 45 (1.51)  
Brain 4 (3.54) 128 (4.28)  
Gallbladder 4 (3.54) 141 (4.72)  
Esophageal  3 (2.65) 56 (1.87)  
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Endometrial 3 (2.65) 59 (1.97)  
Melanoma 3 (2.65) 46 (1.54)  
Sarcoma 3 (2.65) 115 (5.18)  
Gastric/Stomach 3 (2.65) 39 (1.30)  
Ampullary 2 (1.77) 5 (0.17)  
Lung 2 (1.77) 133 (4.45)  
Primary peritoneal 2 (1.77) 17 (0.57)  
Small intestine  2 (1.77) 17 (0.57)  
Renal 2 (1.77) 50 (1.67)  
Fallopian tube and adnexal cancer 1 (0.88) 8 (0.27)  
Vaginal cancer 1 (0.88) 8 (0.27)  
Anal cancer 1 (0.88) 7 (0.23)  
Neuroendocrine 1 (0.88) 44 (1.47)  
Head and neck  1 (0.88) 135 (4.52)  
Bladder 1 (0.88) 28 (0.94)  
Skin (non-melanoma) 1 (0.88) 10 (0.33)  
Cervical 0 (0.00) 53 (1.77)  
Lymphoma 0 (0.00) 17 (0.57)  
Thyroid 0 (0.00) 31 (1.04)  
Thymus 0 (0.00) 9 (0.30)  
Appendiceal 0 (0.00) 4 (0.13)  
Leukemia 0 (0.00) 6 (0.20)  
Germ cell 0 (0.00) 8 (0.27)  
Vulvar  0 (0.00) 4 (0.13)  
Carcinoid tumor 0 (0.00) 8 (0.27)  
Adrenal cancer 0 (0.00) 7 (0.23)  
Cancer of unknown primary 0 (0.00) 35 (1.17)  
Other 0 (0.00) 13 (0.43)  
Not provided 0 (0.00) 607 (20.30)  
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Timing of tumor molecular profiling with 
respect to NCCN guideline change, n (%) 
  0.309 
Before guideline change 91 (80.53) 2,227 (74.48)  
After guideline change 22 (19.47) 682 (22.80)  
Unknown 0 (0.00) 81 (2.71)  
P-values from chi-squared tests and t-tests comparing patients with germline testing and patients without 
germline testing. 
 
The group of people who did not receive germline testing were characterized in more detail and 
compared to the group that had germline testing (Table 2).  Women were significantly more likely to 
receive testing than men (p=0.012). Patients who were diagnosed at a younger age were also 
significantly more likely to receive germline testing (p=0.0020), as well as those that had HBOC-related 
tumors (p>0.001). An informal search of public records determined that, in the group of patients without 
germline testing, 20 of 69 (28.99%) patients died within the first year following tumor-only testing. Two 
of the patients that did not receive germline testing were offered it by a genetic counselor and declined. 
Reasons for declining included difficulty focused around insurance issues, such as difficult 
communication between laboratories and lack of insurance coverage/inability to pay out of pocket for 
testing. 
 
Table 2: Comparing patients with germline testing to patients without germline testing 
Parameters Patients with germline testing (n=44) 




Age at Diagnosis, median (range) 48 (28-75) 57 (17-79) 0.0020 
Sex, n (%)   0.012 
Female 35 (79.55) 39 (56.52) 
 Male 9 (20.45) 30 (43.48) 
Race, n (%)   0.290 
White 33 (75.00) 52 (75.36) 
 Black/ African American 3 (6.82) 7 (10.14) 
Hispanic 3 (6.82) 0 (0.00) 
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Asian 2 (4.55) 4 (5.8) 
Hawaiian/Pacific Islander 1  (2.27) 0 (0.00) 
Other 1 (2.27) 3 (4.35) 
Unknown 1 (2.27) 3 (4.35) 
Timing of tumor molecular profiling 
with regards to guideline change, n 
(%)   
0.783 
Before guideline change 36 (81.82) 55 (79.71) 
 After guideline change 8 (18.18) 14 (20.29) 
Primary tumor site, n (%)   <0.001 
Associated with HBOC 32 (72.73) 25 (36.23) 
 Not associated with HBOC 12 (27.27) 44 (63.77) 
Patient status at the institution, n (%)   0.526 
One-time consult only 8 (18.18) 16 (23.19) 
 Returned for oncology follow-
up 36 (81.82) 53 (76.81) 
Family History, n (%)   0.258 
Significant 12 (27.27) 12 (18.18) 
 Not significant 32 (72.73) 54 (81.82) 
Tumor-only report annotation of 
clinically significant variable, n (%)   0.522 
Actionable 34 (77.27) 52 (75.36) 
 VUS 2 (4.55) 1 (1.45) 
Indeterminate 8 (18.18) 16 (23.19) 
Patient decisions on germline testing 
when seen by genetic counselor at MD 
Anderson, n (%)   
<0.001 
Consented 23 (95.85) 0 (0.00) 
 Declined 1 (4.17) 2 (100.00) 
P-values from chi-squared tests and t-tests comparing patients with germline testing and patients without 






Tumor molecular profiling is a common practice in oncology to aid in determining treatment plans 
for patients. Many genes that are analyzed using tumor molecular profiling overlap with genes that are 
associated with HCPS. Because tumor molecular profiling could potentially be the impetus that prompts 
a patient to present to genetics, it is important to understand the frequency with which that scenario may 
occur to be able to provide adequate informed consent. In this study we specifically characterized the 
patient outcomes of tumor molecular profiling on BRCA1 and BRCA2.  
 
This study found that clinically significant variants in BRCA1/2 are identified in less than 4% of 
tumor-only testing reports. Over the course of almost 6 years, only 113 reports with clinically significant 
variants in BRCA1/2 were identified which is an average of just under 19 patients per year at a single 
institution. This figure provides a convincing argument that it is feasible for every patient with a 
clinically significant variant identified in BRCA1/2 on tumor-only molecular profiling test to be referred 
for genetic counseling and consideration of germline testing. 
 
In order to identify some of the reasons that patients may not have received germline testing, the 
cohort without germline testing was compared to the group with germline testing. First and foremost, 
almost 80% of the cohort with clinically significant variants identified on tumor-only testing without 
germline testing received it before the change in NCCN guidelines in December 2016 that recommends 
that patients with clinically significant variants in BRCA1/2 identified on tumor-only testing receive 
follow-up germline testing. Although these patients were occasionally referred for germline testing prior 
to December 2016 because of their tumor-testing results, they could not always be expected to have been 
because it was not yet considered standard of care. It should be considered, however, that over 80% of 
patients with germline testing received tumor-only testing prior to the guideline change, so there are 
clearly additional factors that are driving germline testing. For example, patients with HBOC-related 
primary tumors are significantly more likely to receive germline testing than those with tumors not 
related to HBOC. This calls to question whether or not this change in NCCN guidelines is common 
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knowledge to all providers regularly ordering tumor molecular profiling tests, as this recommendation is 
listed only in the Genetic/Familial High-Risk Assessment: Breast and Ovarian guidelines. It is possible 
that who do not specialize in breast and/or ovarian cancer may be unaware of its existence. Previous 
studies have identified the need for proper clinical infrastructure when providers are ordering genetic 
testing1,10. It is important that there is an established relationship with providers with clinical genetics 
expertise for the scenarios in which an ordering physician may not have extensive experience with 
hereditary cancer predisposition syndromes.  Providers may also consider retrospectively evaluating any 
patients with tumor profiling tests before 2016 to determine if they are appropriate candidates for 
germline testing. 
 
Other factors could account for the lack of germline testing as well. Over 65% of patients died in 
the first two years following tumor-only testing, indicating that there may have not been sufficient time 
for the patients to receive germline testing. Eighteen of the patients that never received testing (18/69, 
26.09%) could not have reasonably had germline testing at our institution--16 because they were seen 
only once at our institution for a one-time visit, and two that saw a genetic counselor and declined 
germline testing.  
 
There are a number of limitations to our study. Due to the nature of a retrospective chart review, 
there is inherently a limitation due to missing or incomplete data in the patient’s chart. It is possible that 
patients have received germline testing at outside institutions that are not recorded in their charts, or that 
they passed away and it had not been reported. Additionally, this study was performed at a single 
institution in a cohort that consisted mostly of advanced cancer patients, therefore the results may not be 
widely generalizable for all patients who receive tumor molecular profiling. Lastly, this cohort widely 
reflects patients that have received tumor-only testing prior to the NCCN guideline changes to include 
tumor profiling results, so this group may not properly represent the new practices of physicians and 
ordering providers. However, the number of patients that received tumor molecular profiling and have 
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germline PVs in BRCA1/2, as well as the number of patients with germline PVs, are in agreement with 
previous studies2,5,7, indicating that the data is consistent. 
 
These results do indicate, however, that there is a significant number of patients that have not 
received germline testing despite being candidates. There could be many factors that affect this outcome, 
some of which are related to the patient’s personal situation and cannot be controlled. However, many 
barriers to germline testing were identified during this study. For one, despite the fact that tumor-only 
testing reports analyzed include in the interpretation of variants in BRCA1/2 deemed as “actionable” that 
“in the appropriate clinical context, testing for the presence of germline mutations...is recommended,” it 
could be argued that there should be a more prominent indication on the test report recommending that 
the ordering physician refer the patient to genetic counseling if he or she has not already received 
germline testing. Furthermore, it is important for laboratories who perform tumor-only testing to follow 
the recommendations put forth by the Human Genome Variation Society (HGVS) when describing 
variants on reports. HGVS recommends that, in general, “all variants should be described at the most 
basic level, the DNA level. Descriptions at the RNA and/or protein level may be given in addition” and 
that “all variants should be described in relation to an accepted reference sequence.”13 The use of HGVS 
nomenclature is not yet standard reporting practice amongst all laboratories. This can make researching 
the variant increasingly difficult, as the notation provided can be vague and therefore difficult to search 
in ClinVar. Changes to the reports by indicating more obviously that a referral to genetic counseling is 
warranted and by including HGVS-recommended notation could potentially boost the proportion of 
patients that receive follow-up germline testing. 
 
It is also important for ordering physicians to acknowledge the difference between expectations for 
updating tumor-only testing reports and germline testing reports. A consensus position paper by the 
Association of Molecular Pathology, American Society of Clinical Oncology, and College of American 
pathologists recommends that tumor molecular profiling results “should be static, and the date of issue 
should be clearly presented.”14 Therefore it should not be expected of laboratories to update results of 
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tumor molecular profiling, and providers are expected to remain educated about the changes in medical 
knowledge. The importance of this duty by providers can be illustrated when considering the 
implications of the NM_000059.3:c.9976A>T (p.K3326Ter) variant in BRCA2. While this variant is 
truncating, it is a relatively common variant currently classified as benign. Older tumor-only testing 
reports in this study were observed to list the BRCA2 K3326Ter variant as pathogenic.  
 
Lastly, most external laboratory results are transmitted to ordering physicians as a PDF or as a 
hard copy. This in itself is a potential barrier to care, as PDF files (and clearly hard copies) cannot be 
searched through text recognition. Ideally, such results could be uploaded directly to an electronic 
medical record (EMR) in a manner that is immediately searchable and interacts with the rest of the 
database. This way, if a pathogenic variant is identified, there could be an alert, action, or task sent to the 
ordering physician indicating that a referral should be placed for genetic counseling or germline testing 
should be pursued for this patient. A fully functional EMR could benefit the providers and therefore the 
patients by making it easier to recognize the next steps in patient care.  
 
In summary, our study identified that less than 4% patients with tumor molecular profiling reports 
have reported a pathogenic variant in BRCA1/2, and approximately one-third of those patients have had 
germline testing. It is important to note that many of the patients who have not received germline testing 
received tumor-only testing prior to NCCN guidelines changed to include tumor profiling results, and 
that over half of the patients without germline testing died within the first two years following tumor 
profiling. Regardless, due to the fact that almost two thirds of patients with PVs in BRCA1/2 on tumor 
molecular profiling have not received testing, there is concern regarding provider education on the 
NCCN recommendation for follow-up germline testing. Going forward, this problem could be mitigated 
by more obvious notation on tumor molecular profiling reports indicating that patients with clinically 
significant variants identified in BRCA1/2 should receive follow-up, and having providers ordering 
tumor profiling tests establish clinical infrastructure (such as a relationship with a genetic counselor to 
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whom they can make referrals) to ensure any patient with a clinically significant variant identified in 










Variant(s) identified on tumor-only 
testing (gene, variant) 
Variant identified on germline 
testing (gene, variant) 
Primary 
tumor site  
1 BRCA2, A938fs*21; BRCA2, A938P NM_000059.3(BRCA2):c.2808_2
811del (p.Ala938Profs) 
Breast 





4 BRCA1, Q804fs*10 BRCA1, 2529del4† Breast 
5 BRCA2, F1182fs*1 NM_000059.3(BRCA2):c.3545_3
546delTT (p.Phe1182Terfs) 
Breast 
6 BRCA2, E49* NM_000059.3(BRCA2):c.145G>
T (p.Glu49Ter) 
Breast 
7 BRCA2, c.7618-1G>A NM_000059.3(BRCA2):c.7618-
1G>A 
Breast 
9 BRCA1, R496H; BRCA2 S1982fs*22 NM_000059.3(BRCA2):c.391del
T (p.Ser131Profs) 
Ovarian 
10 BRCA2, E1646fs*23 NM_000059.3(BRCA2):c.4936_4
939delGAAA (p.Glu1646Glnfs) 
Breast 
11 BRCA1, E23fs*17 NM_007294.3(BRCA1):c.68_69d
elAG (p.Glu23Valfs) 
Anal cancer 
14 BRCA2, Q548* NM_000059.3(BRCA2):c.1642C>
T (p.Gln548Ter) 
Breast 
16 BRCA2, W1692fs*3 NM_000059.3(BRCA2):c.5073du
pA (p.Trp1692Metfs) 
Breast 
18 BRCA1, V1736A NM_007294.3(BRCA1):c.5207T>
C (p.Val1736Ala) 
Ovarian 
19 BRCA2, A2717S; BRCA2, 
E881fs*14; BRCA2, E880_S884del 
BRCA2, 2869delG† Ovarian 
20 BRCA1, E23fs*17 NM_007294.3(BRCA1):c.68_69d
elAG (p.Glu23Valfs) 
Ovarian 
21 BRCA1, V340fs*1 NM_007294.3(BRCA1):c.1018del
G (p.Val340Terfs) 
Ovarian 





24 BRCA2, H2417fs*3 NM_000059.3(BRCA2):c.7251_7
252delCA (p.His2417Glnfs) 
Prostate 
27 BRCA1, S628fs*2 BRCA1, 1999ins11† Ovarian 
28 BRCA1, M1775R NM_007294.3(BRCA1):c.5324T>
G (p.Met1775Arg) 
Breast 
29 BRCA2, I1151fs*7 BRCA2, 3678insT† Breast 
30 BRCA1, E143* NM_007294.3(BRCA1):c.427G>
T (p.Glu143Ter) 
Breast 





35 BRCA2 Y2215fs*10 NM_000059.3(BRCA2):c.6641du
pC (p.Tyr2215Leufs) 
Pancreas 




Sarcoma of the 
head and neck 
39 BRCA2, L1768fs*5 NM_000059.3(BRCA2):c.5303_5
304delTT (p.Leu1768Argfs) 
Ampulla 
41 BRCA2, 2766fs*11 NM_000059.3(BRCA2):c.8297del
C (p.Thr2766Asnfs) 
Prostate 
43 BRCA1, D821fs*25, BRCA1 P1637L NM_007294.3(BRCA1):c.2457del
C (p.Asp821Ilefs) 
Pancreas 





Variants identified on tumor-only testing were recorded as indicated on the test report. All variants 
identified in BRCA1/2 on tumor-only testing were included. Germline variants are reported as they 
currently appear in ClinVar as of April 28, 2019.  
†Indicates a germline variant that was unable to be located in ClinVar due to limited 
information/alternate notation included on the germline testing report. The nomenclature used on the 
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